VPHM. For instance, RPRX has two at least $500M+ a year Phase III drugs that are almost slam dunks to be approved by the FDA. One is Androxal a pill to fix secondary hypogonadism (low testosterone) and the other is for the untapped markets of uterine fibroids and endometriosis. The market cap of RPRX is $160M - less than a 3rd of VPHM's cash. They could at least buy stock in RPRX and try to gain a 25% stake. Or they could try to buy Androxal for $400M. That is a pile 'o cash just to fund a couple drugs in development. They have Vancocin revenue to do that with anyway.
With $6+ a share in cash versus a $7.70 share price the market has spoken. The market says we aren't sure about your existing revenue stream or your ability to put your cash to work.
News 
Market Data 
Discover 
AI
